<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219332</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-019</org_study_id>
    <nct_id>NCT04219332</nct_id>
  </id_info>
  <brief_title>RCT on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection</brief_title>
  <official_title>Prospective Randomized Controlled Trials on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection in Radical Laparoscopic Gastrectomy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate whether submucosal or subserous injection of
      indocyanine green during laparoscopic lymph node dissection of gastric cancer was different
      in tracing lymph nodes of gastric cancer. The patients with gastric adenocarcinoma (cT1-4a,
      Nmuramel +, M0) were studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, with the successful application of ICG fluorescence imaging technology in
      laparoscopic equipment, scholars have found that ICG near infrared imaging has better tissue
      penetration and can better identify lymph nodes in hypertrophic adipose tissue than other
      dyes under visible light, which makes ICG fluorescence imaging guide laparoscopic radical
      resection of gastric cancer lymph node dissection has become a new exploration direction. ICG
      near-infrared imaging technology has important research value, good application prospect and
      broad development space in laparoscopic radical resection of gastric cancer. However, at
      present, the application of ICG near infrared imaging technology in laparoscopic radical
      resection of gastric cancer is still in the exploratory stage, and there is no unified
      standard.Therefore, in the world, there is still a lack of high-level evidence-based evidence
      of large-sample prospective randomized controlled trials to evaluate the effectiveness,
      safety and feasibility of submucosal or subserous injection of ICG in guiding laparoscopic D2
      radical resection of gastric cancer.The investigator first carried out this study in the
      world to evaluate the lymph node acquisition and perioperative safety of gastric cancer
      patients who received submucosal injection of ICG and subserous injection of ICG during
      laparoscopic radical gastrectomy in the same period, in order to promote the standardized
      development of ICG near infrared imaging in laparoscopic radical gastrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">December 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Retrieved Lymph Nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Total Number of Retrieved Lymph Nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of fluorescent lymph nodes in groups A and B</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Total number of fluorescent lymph nodes in groups A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between fluorescent lymph nodes and positive lymph nodes in groups A and B (positive rate)</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Relationship between fluorescent lymph nodes and positive lymph nodes in groups A and B (positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between fluorescent lymph nodes and negative lymph nodes in groups A and B (false positive rate)</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Relationship between fluorescent lymph nodes and negative lymph nodes in groups A and B (false positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between non-fluorescent and negative lymph nodes in groups A and B (negative rate)</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Relationship between fluorescent lymph nodes and negative lymph nodes in groups A and B (false positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between non-fluorescent lymph nodes and positive lymph nodes in groups A and B (false negative rate)</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Relationship between fluorescent lymph nodes and negative lymph nodes in groups A and B (false positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metastasis Lymph Nodes</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Number of Metastasis Lymph Nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate of lymph node</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Metastasis rate of lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>30 days</time_frame>
    <description>This is for the early postoperative complication, which defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rates</measure>
    <time_frame>30 days</time_frame>
    <description>This is for the early postoperative mortality, which defined as the event observed within 30 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>3-year disease free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>36 months</time_frame>
    <description>Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first ambulation</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation in hours is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first flatus in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first liquid diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first liquid diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first soft diet</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first soft diet in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of weight</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The variation of weight on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of BMI in kg/m^2</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>The variation of BMI in kg/m^2 on postoperative 3, 6, 9 and 12 months are used to access the postoperative nutritional status and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative morbidity rates</measure>
    <time_frame>1 days</time_frame>
    <description>The intraoperative postoperative morbidity rates are defined as the rates of event observed within operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of white blood cell count</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of hemoglobin</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of hemoglobin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of C-reactive protein</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of C-reactive protein IN milligram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of prealbumin</measure>
    <time_frame>Preoperative 3 days and postoperative 1, 3, and 5 days</time_frame>
    <description>The values of prealbumin in gram/liter from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded to access the inflammatory and immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node noncompliance rate</measure>
    <time_frame>1 days</time_frame>
    <description>Lymph node noncompliance was defined as the absence of lymph nodes that should have been excised from more than 1 lymph node station. Major lymph node noncompliance was defined as more than 2 intended lymph node stations that were not removed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Indocyanine Green</condition>
  <condition>Gastric Cancer</condition>
  <condition>Injection Site</condition>
  <arm_group>
    <arm_group_label>Subserosal injection of indocyanine green tracer group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subserosal injection, with a concentration of 0.5 mg / ml, 3 points for each size, 2 ml for each point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Submucosal injection of indocyanine green tracer group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Submucosal injection, concentration of 1.25mg / ml, four points around the lesion, each point 1ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subserosa injection of indocyanine green</intervention_name>
    <description>During the operation, the large and small curvature of the stomach was injected into the subserous layer at 3 points, 0.5mg/ml (2ml/ point).</description>
    <arm_group_label>Subserosal injection of indocyanine green tracer group</arm_group_label>
    <other_name>No other intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>submucosal injection of indocyanine green</intervention_name>
    <description>Before operation, submucosal injection was given at 4 points around the focus, with concentration of 1.25mg/ml and 1ml/ points.</description>
    <arm_group_label>Submucosal injection of indocyanine green tracer group</arm_group_label>
    <other_name>No other intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from over 18 to under 75 years.

          -  Endoscopic biopsy of gastric primary lesions was diagnosed as gastric adenocarcinoma
             (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet
             ring cell carcinoma, and poorly differentiated adenocarcinoma) .

          -  The preoperative clinical staging was cT1-4a, N0-3, and M0, according to the AJCC-7th
             TNM tumor staging.

          -  No distant metastasis was detected before the operation, and the tumor did not
             directly invade the pancreas, spleen and other nearby organs.

          -  Preoperative ECOG physical status score 0-1.

          -  Preoperative ASA score I-III.

          -  Informed consent of the patient.

        Exclusion criteria:

          -  Pregnant or lactating women

          -  Suffering from severe mental illness

          -  History of upper abdominal surgery (except laparoscopic cholecystectomy)

          -  History of gastric surgery (including ESD / EMR for gastric cancer)

          -  Preoperative imaging examination showed regional fusion of enlarged lymph nodes
             (maximum diameter â‰¥3cm)

          -  History of other malignant diseases within 5 years

          -  Neoadjuvant treatment has been implemented

          -  Unstable angina pectoris within 6 months or history of myocardial infarction

          -  History of cerebral infarction or cerebral hemorrhage within 6 months

          -  History of continuous systemic corticosteroid treatment within 1 month

          -  Concurrent surgery for other diseases is required

          -  Gastric cancer complications (bleeding , perforation, obstruction) and need emergency
             surgery

          -  FEV1 of pulmonary function test &lt;50% of the expected value
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Ming Huang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Ming Huang, MD</last_name>
    <phone>86 13805069676</phone>
    <email>hcmlr2002@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi-Yue Chen, PhD</last_name>
    <phone>+8615980235636</phone>
    <email>690934662@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of gastric cancer</name>
      <address>
        <city>FuZhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Ming Huang, MD</last_name>
      <phone>+8613805069676</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010 Mar;251(3):417-20. doi: 10.1097/SLA.0b013e3181cc8f6b.</citation>
    <PMID>20160637</PMID>
  </reference>
  <reference>
    <citation>Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, Ryu SW, Cho GS, Song KY, Ryu SY. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014 Mar 1;32(7):627-33. doi: 10.1200/JCO.2013.48.8551. Epub 2014 Jan 27.</citation>
    <PMID>24470012</PMID>
  </reference>
  <reference>
    <citation>Lucarelli G, Spilotros M, Vavallo A, Palazzo S, Miacola C, Forte S, Matera M, Campagna M, Colamonico O, Schiralli F, Sebastiani F, Di Cosmo F, Bettocchi C, Di Lorenzo G, Buonerba C, Vincenti L, Ludovico G, Ditonno P, Battaglia M. A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review. Medicine (Baltimore). 2016 May;95(19):e3642. doi: 10.1097/MD.0000000000003642. Review.</citation>
    <PMID>27175683</PMID>
  </reference>
  <reference>
    <citation>Samorani D, Fogacci T, Panzini I, Frisoni G, Accardi FG, Ricci M, Fabbri E, Nicoletti S, Flenghi L, Tamburini E, Tassinari D, Gianni L. The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study. Eur J Surg Oncol. 2015 Jan;41(1):64-70. doi: 10.1016/j.ejso.2014.10.047. Epub 2014 Nov 4.</citation>
    <PMID>25468752</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Director, Head of Gastric Sugery, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

